Company Overview and News

 
CODA Biotherapeutics Launches with $19 Million to Tackle Neuropathic Pain

2018-09-12 biospace
Coda Biotherapeutics launched in South San Francisco with a $19 million Series A financing. Lead investors were MPM Capital and Versant Ventures. They were joined by Astellas Venture Management and Novartis.
OREXQ OREX RARE

6
OREX / Orexigen Therapeutics, Inc. 8-K (Current Report)

2018-09-05 sec.gov - 6
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
OREX

85
Tracking Seth Klarman's Baupost Group Holdings - Q2 2018 Update

2018-08-14 seekingalpha - 12
The portfolio continues to be heavily concentrated with the top three positions accounting for ~40% of the 13F portfolio.
PCG NSAM.WI CQP PRTK TWX AKBA AR SCACU CAH TRBAB PBF NSAM SLB GE OREX LNG TRBNW VRTV SYF TWC STNL NRF TBPH SCAC SLB MCK OREXQ ATRA SNTL AGN BIIB DIS QRVO GEC NG VSAT ABC CLNY GNE TRCO

2
Pernix Therapeutics Holdings, Inc. (PTX) CEO John Sedor on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha - 2
Pernix Therapeutics Holdings, Inc. (NYSEMKT:PTX) Q2 2018 Earnings Conference Call August 9, 2018 4:30 PM ET
OREXQ OREX PTX

2
OREX / Orexigen Therapeutics, Inc. 8-K (Current Report)

2018-07-31 sec.gov - 2
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
OREX

6
OREX / Orexigen Therapeutics, Inc. FORM 8-K (Current Report)

2018-07-05 sec.gov - 6
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
OREX

10
Pernix Wins Auction; Orexigen's Sale Of Contrave Looks To Be Complete

2018-06-28 seekingalpha - 3
Orexigen Therapeutics (OREX) will soon be no more. After filing for bankruptcy and placing itself on the auction block, a sole bidder, Nalproprion Pharmaceuticals, has been declared the winner and will acquire essentially all assets and some limited liabilities for a sum of $75 million. In an 8k filed with the SEC, Orexigen informed the bankruptcy court that it received no competing bids and was declaring Nalproprion the winner.
OREXQ OREX

8
OREX / Orexigen Therapeutics, Inc. FORM 8-K (Current Report)

2018-06-22 sec.gov - 1
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
OREX

33
Pernix Therapeutics Announces Result of Bid Process for Acquisition of Worldwide Rights to Contrave® for Weight Loss

2018-06-22 globenewswire - 5
MORRISTOWN, N.J., June 22, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that Nalpropion Pharmaceuticals, Inc. (“Nalpropion”), the special purpose vehicle (“SPV”) created by Pernix and an investor group (collectively with Pernix, the “Investors”), has been informed by Orexigen Therapeutics, Inc. (“Orexigen”) that no other bids for Orexigen’s assets were received by the court-approved bid deadline.
OREXQ OREX PTX

16
OREX / Orexigen Therapeutics, Inc. FORM 8-K (Current Report)

2018-06-06 sec.gov - 9
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
OREX

11
Jaguar Health Appoints Robert J. Griffing Chief Commercialization Officer of Jaguar Subsidiary Napo Pharmaceuticals

2018-05-29 accesswire - 1
SAN FRANCISCO, CA / ACCESSWIRE / May 29, 2018 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has appointed Robert J. Griffing, an accomplished pharmaceutical and biotech executive, as chief commercialization officer of Napo Pharmaceuticals, Inc.
JAGX OREXQ OREX

426
Tracking Seth Klarman's Baupost Group Holdings - Q1 2018 Update

2018-05-15 seekingalpha - 18
The portfolio continues to be heavily concentrated, with the top three positions accounting for one-third of the 13F portfolio.
SGEN PCG NSAM.WI CQP PRTK TWX PXD AR SCACU IMOS CAH PBF NSAM FOX GE AMC OREX LNG VRTV SYF TWC STNL NRF TBPH SCAC SLB FOXA ESRX GTYH MCK CASC OREXQ FWP ATRA SNTL BIIB AGN CI DIS QRVO CLNS GEC RUN KERX NG VSAT ABC T CLNY GNE

29
Pernix Therapeutics' (PTX) CEO John Sedor on Q1 2018 Results - Earnings Call Transcript

2018-05-10 seekingalpha - 1
Pernix Therapeutics Holdings, Inc. (NYSEMKT:PTX) Q1 2018 Earnings Conference Call May 10, 2018 4:30 PM ET
OREXQ OREX PTX

16
OREX / Orexigen Therapeutics, Inc. 8-K (Current Report)

2018-05-04 sec.gov - 9
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
OREX

Related Articles

DMPI: DelMar Pharmaceuticals Analysis and Research Report

19h - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

Silicon Investor Message Boards

This table lists all message boards related to OREX / Orexigen Therapeutics, Inc. on message board site Silicon Investor.

Stocks and Forex Analysis Stocks and Forex Analysis Stocks and Forex Analysis Orexigen - OREX Orexigen - OREX Orexigen - OREX
FOREX - Currency Trading FOREX - Currency Trading FOREX - Currency Trading LETu0027S PLAY IN THE FOREX..AND NOT GET LOST! LETu0027S PLAY IN THE FOREX..AND NOT GET LOST! LETu0027S PLAY IN THE FOREX..AND NOT GET LOST!
Isolyser (OREX)- Any comments Isolyser (OREX)- Any comments Isolyser (OREX)- Any comments ORXX - Orex Gold Mines Corporation ORXX - Orex Gold Mines Corporation ORXX - Orex Gold Mines Corporation
Forex Trading Strategies u0026 System Forex Trading Strategies u0026 System Forex Trading Strategies u0026 System Forex Forum Forex Forum Forex Forum
Precious Metal, FOREX and Commodity Trading--A little Ainu0027t Precious Metal, FOREX and Commodity Trading--A little Ainu0027t Precious Metal, FOREX and Commodity Trading--A little Ainu0027t Endorex (DOR) Endorex (DOR) Endorex (DOR)
CUSIP: 686164104